A unique TARGETED NANOSPHERE (TNS) platform with emerging product candidates that can significantly improve delivery, safety and performance of both existing and developing cancer (and other) therapeutics.

NanoValent Pharmaceuticals, Inc. (NanoValent/NVP) is a privately-held company, collaborating closely with Children’s Hospital Los Angeles (CHLA) as well as other US academic partners. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.